Conference
CUOG PHASE II RANDOMIZED STUDY OF CUSTIRSEN (OGX-011) COMBINATION THERAPY IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER (CRPC) WHO RELAPSED ON OR WITHIN SIX MONTHS OF 1ST-LINE DOCETAXEL THERAPY
Authors
Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Pollak M; Wood L; Winquist E
Volume
181
Pagination
pp. 229-230
Publisher
Wolters Kluwer
Publication Date
April 1, 2009
DOI
10.1016/s0022-5347(09)60654-6
Conference proceedings
Journal of Urology
Issue
4
ISSN
0021-0005